Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance-Reference-Cited by-同舟云学术

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance

Published:2024-07-16 Issue:5 Volume:13 Page:1361-1383
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Yamamura Takashi^ORCID,Isobe Noriko^ORCID,Kawachi Izumi^ORCID,Nohara Chiyoko,Miyazaki Yusei^ORCID,Tomita Minami^ORCID,Tsumuraya Takahiko^ORCID,Yamashita Katsuhisa^ORCID,Nakahara Jin^ORCID,Nakashima Ichiro^ORCID,Fujihara Kazuo^ORCID

Funder

Chugai Pharmaceutical Co, Ltd.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40120-024-00640-7.pdf

Reference23 articles.

1. Holroyd KB, Manzano GS, Levy M. Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol. 2020;31:462–8. https://doi.org/10.1097/ICU.0000000000000703.

2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89. https://doi.org/10.1212/WNL.0000000000001729.

3. Paolilo RB, da Paz JA, Apostolos-Pereira SL, de Rimkus CM, Callegaro D, Sato DK. Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. Arq Neuro-Psiquiatr. 2023;81:201–11. https://doi.org/10.1055/s-0043-1761432.

4. Miyamoto K, Fujihara K, Kira JI, et al. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018;89:667–8. https://doi.org/10.1136/jnnp-2017-317321.

5. Houzen H, Kondo K, Niino M, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology. 2017;89:1995–2001. https://doi.org/10.1212/WNL.0000000000004611.